Intrinsic Alpha

Company Snapshot

Arcus Biosciences, Inc. investment report

Start with RCUS at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.

Arcus Biosciences, Inc.

NYSE:RCUS

Biotechnology

Healthcare
$15.78 -0.39%

-$0.09 today

Market cap
$2.27B
Beta
0.84
P/E (TTM)
-8.2
EPS (TTM)
-$2.94
52W Low $7.91High $28.72

Volume 1.07M

Average 1.17M

Intrinsic Value

RCUS Intrinsic Value

Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.

Arcus Biosciences, Inc.

NYSE:RCUS

Intrinsic Alpha fair value

Locked

Current Price

$15.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Monitor RCUS

Get notified when the price moves into your range

Use alerts to turn the valuation into an action plan instead of checking the stock manually.

Price alerts

Get notified when RCUS drops below your target

Current price baseline

$15.78

Current price

Current price $15.78

Selected target$12.62

Sign in to activate price alerts.

Price History

How has RCUS traded over time?

Review how the market has priced Arcus Biosciences, Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.

Price history

Dividend-adjusted closing price

Period change

-21.96%

Period high

$31.57

Period low

$15.76

Latest

$15.78

Investment Notes

Capture the investment case

Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.

My notes

Journal entries for RCUS

Sign in to keep notes

Keep your research and decisions in your personal journal.

Sign in / Sign up

Fundamental Analysis

Test company quality against your thesis

Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.

Earnings Quality

Follow revenue through to net income

Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.

RCUS Earnings Waterfall · TTM

NYSE:RCUS · Revenue to Net Income

Key Ratios

EPS$-3.93
Gross Margin92.9%
Net Margin-447.8%
P/E Ratio-6.3
P/S Ratio96.9

Analysis

$117.0M of revenue converted into -$452.0M of net income for the selected period. Gross margin is 92.9% and net margin is -447.8%, showing how much revenue survives after costs and taxes. EPS is $-3.93, tying the income statement back to per-share earnings.

Revenue Mix

See which products and regions drive the business

Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.

Revenue by segment

Where RCUS earns its revenue, as reported in company filings

  • License And Development Services
  • Development Services
  • R&D Services
  • License
  • Gilead License to Domvanalimab
  • License and Development Services Revenue
  • Other
Revenue by segment for FY2025
Segment · FY2025 Revenue Share YoY
License And Development Services$221M87.4%—
Development Services$17M6.7%—
R&D Services$8M3.2%—
License$7M2.8%—

Figures in USD. Segments account for 102.4% of reported FY2025 revenue; -$6M is not attributed to a segment. Smaller segments are grouped as "Other".

Financial Position

Check what supports the company underneath the income statement

The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$150.0M
Short-term Investments$552.0M
Receivables$36.0M
Other Current$18.0M
Total Current Assets$756.0M
PP&E (Net)$36.0M
Long-term Investments$73.0M
Other Non-current$59.0M
Total Non-current Assets$168.0M
Total Assets$924.0M

Analysis

Selected assets total $924.0M for Latest. The largest visible component is Short-term Investments at $552.0M, about 59.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Cash Generation

Test whether profit turns into cash

Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$353.0M
+ D&A$10.0M
+ Stock-Based Comp$60.0M
+ Deferred Tax$0
- Working Capital-$194.0M
- Other Non-Cash-$5.0M
= Operating Cash Flow-$482.0M
- Capex-$2.0M
= Free Cash Flow-$484.0M

Analysis

FY2025 free cash flow is -$484.0M. FCF conversion is 137.1% of net income. Operating cash flow was -$482.0M, with capex of -$2.0M. The largest bridge item is Working Capital at -$194.0M.

Quality Snapshot

Check the numbers that compound value

Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/A+30.2%-4.3%
Equity
N/AN/A-13.6%+9.1%
Cash
N/AN/A+2.5%+48.0%
ROIC
N/A-26.9%-38.0%-41.9%

Analysis

Latest growth is strongest in Cash at +48.0% and weakest in ROIC at -41.9%. Three-year average ROIC is -38.0%, which helps show whether that growth is being earned efficiently.

Growth Profile

Compare historical growth with forward expectations

Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A+30.2%
+30.1% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +30.2% over three years. Forward estimates point to Revenue at +30.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Management

Judge how Arcus Biosciences, Inc. allocates capital

Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.

Capital Efficiency

Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-55.9%

avg -36.5%

ROIC

-41.9%

avg -27.2%

ROA

-31.0%

avg -22.0%

Analysis

ROA is currently the strongest return metric at -31.0% versus its period average of -22.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Dividend Record

A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.

Dividends

Dividend history, growth & yield

Dividends

Yield

0.00%

Annual Div/Share

$0.00

Payout Ratio

0.0%

Frequency

—

Shareholder Yield

0.00%

Next Ex-Date

Not announced

Next Payment

—

Analysis

The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.

Owner Returns

Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.

Shareholder Returns

Dividend, buyback & debt paydown yields

Management

Dividend Yield (TTM)

0.00%

Buyback Yield (TTM)

0.00%

Debt Paydown (TTM)

0.00%

Total Yield (TTM)

0.00%

Showing limited history. Sign in for more

Analysis

Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.

Insider Activity

Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.

Insider Trading

SEC Form 4 transactions — last 12 months

Management

Buys

0

$0.00

Sells

32

$9.46M

Net Transaction Value

−$9.46M

Net selling

Most Active

Jaen Juan C.

13 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 21, 26

Azoy Alexander

Direct

Sell$84.8K
Jul 10, 26

Jaen Juan C.

Indirect

Sell$7.9K
Jul 10, 26

Jaen Juan C.

Indirect

Sell$566.4K
Jul 9, 26

Jaen Juan C.

Indirect

Sell$1.5M
Jun 24, 26

Jaen Juan C.

Indirect

Sell$190.7K
Jun 23, 26

Jaen Juan C.

Indirect

Sell$47.6K
Jun 23, 26

Jaen Juan C.

Indirect

Sell$389.5K
Jun 22, 26

Jaen Juan C.

Indirect

Sell$249.7K
Jun 1, 26

Azoy Alexander

Direct

Sell$66K
May 11, 26

Goeltz II Robert C.

Direct

Sell$199K

1–10 of 32

Summary

Insiders reported 0 buys worth $0.00 and 32 sells worth $9.46M over the last 12 months. That adds up to net selling of $9.46M. Jaen Juan C. was the most active insider with 13 transactions.

Leadership

Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.

Management

Key executives, compensation & ownership

View management
NameTitleCompensationAgeShares OwnedOwnership %

Terry J. Rosen

Co-Founder, Chairman & Chief Executive OfficerUSD 1.45M66315.00K0.31%

Juan Carlos Jaen

Co- Founder & PresidentUSD 1.01M68——

Richard A. Markus

Chief Medical OfficerUSD 933.88K———

Robert C. Goeltz

Principal Financial Officer & Chief Financial OfficerUSD 792.69K53——

Carolyn C. Tang

General Counsel & Corporate SecretaryUSD 603.2K470<0.01%

Alexander Azoy

Chief Accounting Officer—503.07K<0.01%

Pia Eaves

Vice President of Investor Relations & Strategy————

Holli Kolkey

Vice President of Corporate Communications————

K. Christopher Garcia

Co-Founder & Member of Scientific Advisory Board————

Jonathan Yingling

Chief Scientific Officer—57——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 21, 2026.

Alternatives to RCUS

Compare Arcus Biosciences, Inc. with similar companies

A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.

Analysts

What Wall Street expects from RCUS

Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.

Analyst Targets

See where analysts expect RCUS to trade next

Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for RCUS.

Sign in free

Analyst Ratings

How analysts rate RCUS today

See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for RCUS.

Sign in free

Company Overview

Understand how Arcus Biosciences, Inc. makes money

Ground the financial evidence in the company profile, business description, and key facts.

Key Information

Filings
NameArcus Biosciences, Inc.
TickerRCUS
ExchangeNew York Stock Exchange
IPO DateMar 15, 2018
IndustryBiotechnology
SectorHealthcare
Market Cap$2.27B
Shares Out100.67M
LocationHayward, CA, US

Stock Analysis

Turn the RCUS report into your next decision

Record your conclusion, evidence, and concerns in a structured analysis workspace.

Investment analysis

Turn RCUS research into a decision

Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.

NYSE:RCUS
Know the Business
Test the Moat
Management
Intrinsic Value

Sign in on the next page to save a private analysis.

Start analysis

FAQ

Common questions about RCUS

Resolve the remaining questions before moving into the detailed workspaces.

Explore

Continue your research

Open the detailed valuation, financial, health, and management workspaces.